Document is current
Any future updates will be listed below
-
Authors
Rondeau, Justin D.
Van de Velde, Justine A.
Bouidida, Yasmine
Sonveaux, Pierre
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Marie Sklodowska-Curie Actions (860245 THERADNET)
HORIZON EUROPE Marie Sklodowska-Curie Actions (860245 THERADNET)
French Community of Belgium (n/a)
French Community of Belgium (n/a)
Communauté Française de Belgique (Actions de Recherche Concertées ARC 21/26-118)
Fonds De La Recherche Scientifique - FNRS (CDR J.0191.24)
- License Information
-
More Information
Article History
Received: 13 February 2024
Accepted: 26 June 2024
First Online: 8 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: P.S. is an inventor of patent application WO2022243541 “Molecular signature for assessing the responsiveness of cancer to mitochondria-targeted antioxidants”, and is involved in a clinical collaboration with Antipodean Pharmaceuticals Inc. for the prevention of breast cancer metastasis. Authors declare no other conflict of interest. In particular, Antipodean Pharmaceuticals Inc. and MitoQ Inc., who possess patent rights on the MitoQ molecule, did not fund the study. Neither them nor the funders were involved in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
